A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment
PHASE3CompletedINTERVENTIONAL
Enrollment
724
Participants
Timeline
Start Date
May 31, 2003
Study Completion Date
May 31, 2004
Conditions
Cognition DisorderNervous System DiseasesMental DisordersBrain Diseases
Interventions
DRUG
galantamine hydrobromide
All Listed Sponsors
lead
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
INDUSTRY
NCT00240695 - A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment | Biotech Hunter | Biotech Hunter